52results about How to "Lower dose level" patented technology

The present invention includes systems and methods for decreasing the pain and discomfort commonly associated with endoscopic procedures, where such procedures may be performed with lower dosage levels of sedative and analgesic drugs. The invention includes use of an anesthetic collar coupled to an endoscope with a flexible shaft. The anesthetic collar allows lubricants, local anesthetics, dyes, and/or other desirable fluids to be passed through the existing lumen of the flexible shaft into an annulus, where the fluid may be distributed through expulsion pores into the gastrointestinal tract. Utilizing the existing lumens found in endoscopes, the present invention allows those fluids that may reduce the pain and discomfort associated with endoscopies such as, for example, local anesthetics and lubricants, to be distributed in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, where such fluids may reduce the drug level requirements for sedative and analgesic agents. Alternatively, the endoscope may be redesigned for streamlined integration with the anesthetic collar or to accomplish the same function of distributing local anesthetics and lubricants, in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, The invention can also be used with endoscopes without existing lumens.

The present invention is drawn to methods for photodynamic therapy (PDT) of a target cell, target tissue or target composition in a mammalian subject, using a therapeutically effective amount of a targeted substance, which is either a targeted photosensitizing agent, or a photosensitizing agent delivery system, or a targeted prodrug. This targeted substance preferably selectively binds to the target cell, target tissue or target composition. Light at a wavelength or waveband corresponding to that which is absorbed by the targeted substance is then administered. The light intensity is relatively low, but a high total fluence is employed to ensure the activation of the targeted photosensitizing agent or targeted prodrug product.

The invention discloses a neutron moisture gauge detector which comprises a housing, a cadmium plate layer wrapped on the outer wall of the housing and a neutron source arranged at a vertical center of the cavity of the housing, wherein a back reflection plate closely connected with the inner wall of the housing and the outer wall of the neutron source is horizontally arranged in the cavity of the housing, an electronics unit mainly composed by a high voltage module and a signal processing module is arranged at the bottom of the cavity of the housing, residual space in the cavity of the housing below the back reflection plate is filled with shielding layers, a plurality of sets of counting tube supports symmetrically arranged from interior to exterior and counting tubes installed on the supports are arranged around the head of the neutron source in space in the housing above the back reflection plate, the root parts of the supports are fixed on the back reflection plate, the counting tubes are installed to form a rectangular array, the height of the counting tubes on the supports gradually increases from interior to exterior to form ladder distribution, an inclined plane reflection plate in a loop corridor is arranged around the counting tubes on the supports, the sidewall of the inclined plane reflection plate is fixed on the sidewall of the housing, and the bottom of the inclined plane reflection plate is fixed on the back reflection plate. The neutron moisture gauge detector provided by the invention has the advantages of good sensitivity, high usage efficiency of the neutron source and the like.

The present invention discloses compounds according to Formula I:

Wherein R^1a, R^1b, R², R⁴, R⁵, R^6a, R^6b, R⁷, R⁸, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

The present invention relates to an implantable drug delivery device comprising a polymeric or polymeric containing material in combination with a therapeutic compound effective for the treatment of a member of the herpesvirus family, wherein the therapeutic compound is in an amount that will effectively treat HSV-1, HSV 2 and/or VZV or reduce reactivation, and wherein the implantable drug delivery device is positioned at or near the site of latent infection or at the site of observed clinical symptoms. The therapeutic compound may include any active antiherpes agent including acyclovir, guanosine, valacyclovir or functionally active analogues.

The invention relates to a reactor pressure vessel simulation test platform for a nuclear power plant. The reactor pressure vessel simulation test platform comprises a test platform base, a plurality of test platform support upright columns whose bottom ends are fixed to the test platform base, a pressure vessel simulation flange fixed to the top ends of the test platform support upright columns, a personnel operation platform fixed to the test platform support upright columns through an oblique support, a test platform crosspiece which is fixed among the test platform support upright columns and has an upper layer, a middle layer and a lower layer, a test platform ladder respectively fixed to the test platform base and the test platform crosspiece, a simulation pressure vessel cylinder wall vertical plate fixed to neighboring layers of the test platform crosspiece, and a test platform simulation pool fixed on the test platform base. The reactor pressure vessel simulation test platform can be installed in a proper workshop outside a reactor containment vessel in a nuclear power plant area. Before a set is shut down and the maintenance work begins, debugging, verifying of special-purpose tools and personnel training work can be finished.

The invention discloses a floating nuclear power station reactor compartment arrangement structure which comprises a double-shell ship body arranged on an offshore nuclear power platform, wherein a primary containment vessel and a spent fuel storage cabin are arranged in an inner cavity of the double-shell ship body; a reactor and primary loop system equipment are arranged in the primary containment vessel; a spent fuel storage facility is arranged in the spent fuel storage cabin; the bottoms and the side faces of the primary containment and the spent fuel storage cabin are elastically connected with the double-shell ship body through elastic connecting structures; a nuclear fuel loading and unloading cabin is arranged on the upper portions of the primary containment and the spent fuel storage cabin; and communication ports are formed between the nuclear fuel loading and unloading cabin and the primary containment and between the nuclear fuel loading and unloading cabin and the spent fuel storage cabin respectively. The nuclear fuel tank has three functions of containment, nuclear fuel loading and unloading and spent fuel storage, and has the characteristics of regular appearance,compact layout, low design pressure and light shielding weight; and an elastic connecting structure is provided, so that the safety of the reactor cabin is further improved.

The use is provided of a calcitonin in the preparation of a medicament for the treatment of an inflammatory disease or condition. The calcitonin may be selected from the group consisting of human, salmon, eel, porcine, bovine, or chicken calcitonin or a derivative, a fragment or a variant thereof. The inflammatory disease or condition may be rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), osteoarthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), lupus erythamatosis, multiple sclerosis (MS), asthma, or immuno-suppressive therapy (e.g. post transplantation surgery). The treatment may also comprise administration of a glucocorticoid, an anti-rheumatic drug or an antibody.

The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.

A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.

Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H₁-receptor agonist, a histamine H₂-receptor agonist, or a histamine H₃-receptor antagonist, and (iv) a β₂-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.

A deinking method using a cellulase which enables the load upon the environment to be reduced; and an evaluation method whereby a cellulase effective in deinking and the effective addition level of the cellulase can be appropriately determined. By proposing pulp-swelling activity (PSA) that elevates the water-retention value of pulp after pulp is reacted with cellulase, it becomes possible to select an enzyme that is effective in cellulase-deinking treatment without lowering the paper strength and to determine the effective enzyme dosage. Namely, a method of deinking waste paper is provided wherein the selection of an effective cellulase and the optimization of the enzyme dosage with the use of PSA as an indication make it possible to minimize the cellulase addition level and lessen the amount of the deinking agent.

The present invention discloses salts of a Compound 1:

useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

The invention discloses a shielding structure, a shielding assembly and a sodium-cooled fast reactor. The shielding structure comprises a plurality of circles of shielding pieces arranged in the radial direction of the shielding structure, wherein each circle of shielding piece is composed of a plurality of graphite shielding rods forming a circle in a surrounding mode, each graphite shielding rod is formed by splicing a plurality of graphite rods in the axial direction, and the splicing seam positions of the graphite shielding rods arranged in the radial direction of the shielding structure are not completely the same. According to the technical scheme, part of neutrons escaping outwards from the abutted seam position of the graphite rod can be reduced, and the dosage level of the sodium-cooled fast reactor body is reduced.

This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.